Later, it was demonstrated that the treatment of leronlimab antibody (CCR-5 blocker) restores the levels of CD4+ and CD8+ T cells, reduces plasmatic IL-6, and decreases the SARS-CoV-2 viremia [173]. Here, CD8A is linked to COVID-19.